Tempest Therapeutics, Inc. Retained Earnings
Tempest Therapeutics, Inc. (TPST) had Retained Earnings of -$275.32 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$275.32M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$270.07M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$233.37M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$229.35M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$275.32M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$270.07M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$233.37M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$229.35M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$225.84M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$217.97M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | -$207.11M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$193.29M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$182.74M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | -$173.17M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$165.26M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$157.78M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | -$150.99M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$143.41M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | -$135.77M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$126.67M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$117.72M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$108.55M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$100.06M 10-K · filed 2023-03-22 | |
| 2021-09-30 | -$92.28M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | -$84.17M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$100.06M 10-Q · filed 2022-05-13 | -$253.45M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$71.76M 10-K · filed 2022-03-29 | -$245.06M 10-K · filed 2021-03-29 |
| 2020-09-30 | -$71.76M 10-Q · filed 2021-11-10 | -$237.70M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$231.32M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$220.65M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | -$208.65M 10-K · filed 2021-03-29 | |
| 2019-09-30 | -$195.96M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$184.32M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | -$174.45M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | -$164.09M 10-K · filed 2020-03-11 | |
| 2018-09-30 | -$322.23M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$316.55M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$308.85M 10-Q · filed 2018-05-03 | |
| 2017-12-31 | -$136.89M 10-K · filed 2019-04-01 | -$301.48M 10-K · filed 2018-03-15 |
| 2017-09-30 | -$292.95M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | -$283.58M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$265.40M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$250.18M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$227.53M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | -$208.24M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$189.68M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$167.92M 10-K · filed 2017-03-02 | |
| 2015-09-30 | -$147.32M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$129.39M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$111.90M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$94.70M 10-K · filed 2016-02-26 | |
| 2014-09-30 | -$75.81M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | -$62.88M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | -$52.99M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | -$45.18M 10-K · filed 2015-03-16 | |
| 2013-09-30 | -$34.18M 10-Q · filed 2013-11-13 | |
| 2013-06-30 | -$27.29M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | -$21.29M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | -$16.13M 10-K · filed 2014-02-27 | |
| 2012-09-30 | -$11.94M 10-Q · filed 2012-11-13 | |
| 2012-06-30 | -$8.82M 10-Q · filed 2012-08-14 | |
| 2011-12-31 | -$2.62M 10-K · filed 2013-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |